Healthcare Marketing Blogs
05|06|26
EVERSANA Appoints Agency and Commercialization Veteran Mike Guarino to Lead Global Agency EVERSANA INTOUCH
EVERSANA appoints Mike Guarino as CEO of EVERSANA INTOUCH to drive AI-powered, data-driven marketing innovation for life sciences brands.
04|22|26
Reimagining Annual Brand Planning With AI
In a recent article for PM360, Chief Strategy Officer John Kenny explores how AI is reshaping the annual brand planning process from a one-time exercise into a more dynamic, insight-driven model that better reflects today’s complex market realities.
04|08|26
The Fourth Hurdle: In the Search for Truth, Will an Algorithm Find Your Drug?
Launch success once depended on approval, access, and adoption, but today, algorithms have become the new gatekeepers. As the patient journey becomes a data journey, this POV, authored by Barry Vucsko, SVP, Strategic Development, examines what it means for marketers when machines decide what evidence rises to the top.
03|17|26
4th Annual Brand Planning Report: Fueling Brand Plan Success Through AI‑Powered Integration
In our fourth annual report, Chief Strategy Officer at EVERSANA INTOUCH, John Kenny, and Senior Partner of EVERSANA MANAGEMENT CONSULTING, Sean Rapson, explore the state of brand planning with input from pharma marketing executives, uncovering persistent gaps in efficiency, consistency, and the ability to harness data effectively.
03|13|26
FDA Warning & Untitled Letters: What Pharma Marketers Need To Know
The FDA’s recent untitled letters signal heightened scrutiny of promotional practices. Download the POV to learn what pharma marketers need to know, and how to proactively mitigate risk while staying compliant.
03|04|26
Rare Disease in Focus: How Innovation Is Accelerating Access for Patients
The rare disease landscape has long been defined by delay, with families frequently facing 7–10 years before receiving a diagnosis. In recognition of Rare Disease Day, Ann Cave, President, Full-Service Agency, wrote an article for PM360 spotlighting how innovation and human insight are reshaping the rare disease landscape.
03|02|26
Creative That Connects: Earning Trust in Rare Disease Communities
In honor of Rare Disease Day, Patrick Brodfuehrer penned an article in Med Ad News that explores what authentic connection really means for the 300 million people worldwide living with a rare disease.
02|13|26
The “Pharma Bowl”: How Super Bowl 60 Became Pharma’s Biggest Stage
From GLP‑1 dominance to celebrity‑driven disease awareness, Super Bowl 60 marked a tipping point in how healthcare brands show up on the world’s biggest advertising stage. What was once considered a high‑risk investment is now a calculated brand‑building move, signaling a shift in how pharma thinks about cultural relevance, storytelling, and long‑term equity.
01|30|26
Mind + Machine: How 2026 Brands Will Win the Future of Pharma Marketing
In our recent webinar, leaders across strategy, creative, technology and omnichannel disciplines explored one essential question: How do 2026 brands win in a rapidly transforming healthcare ecosystem?
01|09|26
The Omnichannel Renaissance: What’s Next for Pharma in 2026?
The life sciences industry is entering a new era. In a recent article penned for Med Ad News, Dan Gandor, EVP of Omnichannel Strategy, coined this the “Omnichannel Renaissance.”